Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $393,300.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $26.22, for a total value of $393,300.00. Following the sale, the chief marketing officer directly owned 15,000 shares in the company, valued at $393,300. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, April 1st, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.46, for a total value of $441,900.00.
• On Friday, March 20th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $49.10, for a total value of $736,500.00.
• On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00.

Maze Therapeutics Price Performance

NASDAQ:MAZE opened at $25.03 on Thursday. Maze Therapeutics, Inc. has a 52 week low of $9.73 and a 52 week high of $53.65. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $1.39 billion, a PE ratio of -9.89 and a beta of 2.50. The stock’s 50-day moving average price is $32.19 and its 200-day moving average price is $37.81.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. As a group, equities analysts expect that Maze Therapeutics, Inc. will post -2.65 EPS for the current fiscal year.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Neutral Sentiment: HC Wainwright trimmed earnings estimates for Maze Therapeutics across multiple periods, including Q2 2026, Q3 2026, Q4 2026, full-year 2026, and longer-term years through 2030. While the firm kept a Buy rating and $110 price target, the lower EPS forecasts suggest analysts see a slower earnings path ahead.
• Negative Sentiment: Maze Therapeutics CEO Jason Coloma sold 1,938 shares in a pre-arranged Rule 10b5-1 plan. Even though the sale was planned and relatively small, insider selling can still weigh on investor sentiment, especially when paired with weaker analyst estimates.
• Negative Sentiment: The company recently reported quarterly EPS of ($0.45), missing expectations by a small margin. That earnings miss, combined with continued losses projected for the year, reinforces concerns that profitability may take time to materialize.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada lifted its stake in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Maze Therapeutics in the 4th quarter valued at about $39,000. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics in the 4th quarter valued at about $43,000. California State Teachers Retirement System lifted its stake in Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. raised their target price on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, March 31st. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Wedbush raised their target price on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 16th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Maze Therapeutics has an average rating of “Buy” and an average target price of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.